Artiva Biotherapeutics, Inc.
ARTV Healthcare Biotechnology
Artiva Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $251,000.00, down 99.3% from fiscal 2023. In the quarter to June 2026, EPS grew 27.6% and free cash flow grew 13.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ARTV
Artiva Biotherapeutics, Inc. (ARTV) Altman Z-score
Artiva Biotherapeutics, Inc.'s Altman Z-score for fiscal 2024 is 1.27, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2024 | 1.27 | — |
How fiscal 2024’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.84 | — | 1.01 | |
| Retained earnings / total assets | (1.18) | — | −1.65 | |
| EBIT / total assets | (0.32) | — | −1.06 | |
| Market value of equity / total liabilities | 4.95 | — | 2.97 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | 1.27 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 8.07 | ||
Z and Z″ put Artiva Biotherapeutics, Inc. in different zones: distress zone by Z, safe zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| FULC Fulcrum Therapeutics, Inc. compare | 8.2× |
| ARTV Artiva Biotherapeutics, Inc. | 1.3× |
| ARCT Arcturus Therapeutics Holdings Inc. compare | −0.6× |
| SRZN Surrozen, Inc. compare | −7.5× |
| OCGN Ocugen, Inc. compare | −13.4× |
| AGEN Agenus Inc. compare | −14.2× |
| BNTC Benitec Biopharma Limited compare | −66.0× |
| CTNM Contineum Therapeutics, Inc. compare | — |
| NAUT Nautilus Biotechnology, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets